TrialAdvances in therapy2023

Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications.

Peter C Taylor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.